Actinium Pharmaceuticals to Host KOL Investor Call at 8am ET Today to Highlight Revamped Clinical Programs and Expanded Market Opportunities Including Newly Initiated Actimab-A Solid Tumor Program

Core Insights - Actinium Pharmaceuticals is presenting three multi-billion-dollar market opportunities for its products Actimab-A and Iomab-ACT in the treatment of myeloid malignancies, solid tumors, and cell & gene therapy conditioning [1][2] Group 1: Actimab-A Developments - Actimab-A is being positioned as a mutation-agnostic backbone therapy for myeloid malignancies, including acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) across various treatment settings [2][3] - Clinical results for Actimab-A show high rates of Complete Remissions (CR) and measurable residual disease (MRD) negativity in relapsed/refractory AML patients, leading to improved survival outcomes [3][4] - A pivotal Phase 2/3 clinical trial for Actimab-A in relapsed/refractory AML is planned, along with trials under a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) [1][3] Group 2: Solid Tumor Program - Actinium is advancing a solid tumor program for Actimab-A, which includes head-to-head clinical trials evaluating its combination with PD-1 inhibitors like KEYTRUDA and OPDIVO against these inhibitors alone [1][3] - The trials will initially focus on patients with head and neck squamous cell carcinoma and non-small cell lung cancer [1] Group 3: Iomab-ACT and Future Prospects - Iomab-ACT is being developed as a universal targeted conditioning agent to enhance patient access to cell and gene therapies and improve outcomes [2][3] - Actinium is also seeking a strategic partner for Iomab-B, which serves as an induction and conditioning agent prior to bone marrow transplant in patients with relapsed/refractory AML [4]